Chroniques génomiques - Dépistage du cancer : les promesses illusoires de Pathway Genomics

Abstract

The “liquid biopsy” approach shows promise for characterization and monitoring of cancer during treatment; however a blood-based detection test for “high-risk” but asymptomatic individuals, recently introduced by Pathway Genomics, lacks supporting data and has no proven clinical utility.